← Back to Clinical Trials
Recruiting NCT06742528

NCT06742528 Comparison Of Efficacy Of Iron Polymaltose Complex And Ferrous Sulphate In Iron Deficiency Anemia In Pediatric Patients

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06742528
Status Recruiting
Phase
Sponsor Arooj Khan
Condition Iron Deficiency Anemia
Study Type INTERVENTIONAL
Enrollment 198 participants
Start Date 2024-01-10
Primary Completion 2024-12-25

Eligibility & Interventions

Sex All sexes
Min Age 6 Months
Max Age 5 Years
Study Type INTERVENTIONAL
Interventions
Ferrous sulfateIron Polymaltose Complex

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 198 participants in total. It began in 2024-01-10 with a primary completion date of 2024-12-25.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to compare the efficacy of two iron preparation for the management of children presented with iron deficiency anemia. Ferrous sulphate and lron polymaltose (ferric form) are most commonly used preparations. Both drugs are easily available in market and are often recommended by pediatriclans. The efficacy, bioavail.tbilily, side effects and cost of these preparations vary. This study is designed to find out a drug with better efficacy that can be used for treatment of iron deficiency anemia in local population.

Eligibility Criteria

Inclusion Criteria: * Patients having iron deficiency anemia Exclusion Criteria: 1. Patients diagnosed as congenital aplastic anemia or thalassemia (Determined from medical record). 2. Patients who were transfused in previous 4 weeks (will be determined on history) 3. Children having mal-absorption syndrome and diarrheal illnesses. (will be determined on history and medical record) 4. Gastrointestinal bleeding suggested by history of hematemesis (bloody vomit), melena (black colored stools) or bloody stools.

Contact & Investigator

Central Contact

Aimal Khan, MBBS

✉ aimalkhan871207@gmail.com

📞 03481903336

Frequently Asked Questions

Who can join the NCT06742528 clinical trial?

This trial is open to participants of all sexes, aged 6 Months or older, up to 5 Years, studying Iron Deficiency Anemia. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06742528 currently recruiting?

Yes, NCT06742528 is actively recruiting participants. Contact the research team at aimalkhan871207@gmail.com for enrollment information.

Where is the NCT06742528 trial being conducted?

This trial is being conducted at Peshawar, Pakistan.

Who is sponsoring the NCT06742528 clinical trial?

NCT06742528 is sponsored by Arooj Khan. The trial plans to enroll 198 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology